<DOC>
	<DOCNO>NCT02464631</DOCNO>
	<brief_summary>In prospective randomize trial , A Minimum 300 consecutive patient decompensated HCV ( Hepatitis C Virus ) relate cirrhosis , present Institute Liver Biliary Sciences hospital include patient meet entry criterion receive treatment 400 mg Sofosbuvir , administer orally daily , Ribavirin administer orally twice daily , dos determine accord body weight ( 600 mg daily patient body weight ≤60 kg,800 mg daily patient weigh &gt; 60 ≤80 kg , and1000 mg daily patient body weight &gt; 80 kg ) . Based treatment duration , patient would randomize either 3 treatment group - - Group 1 - Sofosbuvir + Ribavirin x 24 week - Group 2 - Sofosbuvir + Ribavirin x 36 week - Group 3 - Sofosbuvir + Ribavirin x 48 week</brief_summary>
	<brief_title>To Evaluate Safety Efficacy Sofosbuvir Ribavirin Patients With HCV ( Genotype 3 ) Related Decompensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Male Female ≥ 18 yr Baseline HCV RNA &gt; 1000 IU/ml Cirrhosis current prior decompensation HCV ( Hepatitis C Infection ) Genotype 3 Treatment naïve treatment experience HIV HBV ( Hepatitis B Virus ) coinfection Recent Variceal bleed Pregnancy Haemolytic anaemia Platelet count &lt; 20,000/ml Advanced HCC ( Hepatocellular Carcinoma ) Renal dysfunction , GFR ( glomerular filtration rate ) &lt; 30 ml/min Haemoglobin &lt; 10 g/dl MELD ( Model End Stage Liver Disease ) &gt; 25 , CTP ( ChildTurcottePugh score ) &gt; 12 Post organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>